Sanofi Consumer Healthcare India Limited has announced a robust financial performance for the first quarter of FY26, with net profit soaring by 36% to ₹67.8 crore. The company's revenue also saw a significant increase of 33%, reaching ₹229.2 crore for the quarter.
Product Relaunches Drive Domestic Growth
A key factor in this impressive growth was the strategic relaunch of products that had been voluntarily recalled last year. These relaunches, including popular items such as DePURA 60K and Combiflam Suspension, propelled domestic sales up by 15.5%.
The company noted that its domestic business outperformed the broader market, achieving both market share gains and substantial volume growth. In addition to strong domestic figures, export sales surged by an impressive 144%, albeit from a lower base.
Commenting on the results, Himanshu Bakshi stated, “Our performance this quarter reflects consistent and disciplined execution across our key markets. The domestic business outpaced the market, delivering both market share gains and volume growth, while exports made a meaningful contribution to overall results.” He added, “Guided by science and driven by purpose, we remain committed to simplifying self-care and making it more accessible and effective for consumers.”
Independent Entity Driving Self-Care Innovation
Sanofi Consumer Healthcare India became an independent entity in June 2024, following its demerger from Sanofi India Limited. The company operates in the consumer healthcare segment, managing well-known brands such as Allegra, DePURA, Avil, and Combiflam. This independence appears to be fostering agile strategies that are translating into strong financial outcomes and market leadership in the self-care sector.